Recent studies have dwelled on the escalating trend of the fungal infection, Candida auris, which has been on a disturbing rise. Notably, this increase is not contained to only single-source cases, but also, manifold sources have been spawning the infection. C. auris, ever since its first reported US case in 2016, has been recognized as an ‘urgent antimicrobial resistance threat’ prevalent in hospitals.
This declaration was made by the authoritative Centers for Disease Control and Prevention (CDC). The new research data zeroes in on a comprehensive health system located in Miami, Florida, and the findings are quite concerning. The number of cases flagged off as clinical in nature has seen an eye-opening leap from a mere 5 in 2019 to an alarming 115 in 2023.
This exemplifies a staggering 2200 percent increase within a span of four years. The research team from the US has penned in their published paper, ‘In alignment with the US national trends, we observed C. auris spreading precipitously in our community. This can be deduced from the spurt in the identification of C. Auris from clinical cultures notably in 2020 and 2021, followed by a less steep but definite rise in 2022 and 2023.’
A bleak aspect is that a multitude of C. auris strains display resistance to standard treatments. Even common disinfectants and cleaners found ineffective against them. In hospitals, the fungus multiplies aggressively, often transmitted via medical equipment such as catheters, feeding and breathing tubes. Once C. auris gets an upper hand, the ensuing infection manifests into serious and potentially fatal illnesses impacting the bloodstream, respiratory system, central nervous system, and even organs and skin.
That said, for the general public, the risk of contacting the infection is relatively low. Most healthy individuals have minimal exposure to C. auris and their robust immune system capably repels it. However, for patients already grappling with health issues and stationed in the hospital, the escalating threat of infection is palpably real. Bloodstream infections are the most recurrent, but a sharp increase in infections in soft tissues or bones and in the cerebrospinal fluid has been noted.
Managing C. auris becomes more arduous as its outbreaks cover more grounds. What the US is going through seems to be echoed across the globe. Health professionals have been wrestling with containing C. auris ever since it was first discovered in Japan back in 2009. The first US cases emerged in 2016. Violent alarms have been raised about the formidable threat posed by this fungus. A poignant example came two years ago when news about C. auris infection reaching half the American states made headlines.
However, as the Miami study exposes, the surge persists relentlessly. The CDC has meticulously drafted an exhaustive list of recommendations to impede the spread of C. Auris infections. The suggestions stress on conscientious cleaning routines for surfaces and devices and advocate the use of single-occupancy rooms wherever feasible. As the researchers point out, ‘Infection prevention strategies have to revolve around isolation and contact precautions.
Our study implies that prompt identification of patients harboring C. Auris and swift implementation of preventive measures can potentially influence the incidence of bloodstream-related infections.’ This critical research has been published in the esteemed American Journal of Infection Control.
Source: https://www.sciencealert.com/dangerous-fungal-infection-sees-a-dramatic-increase-in-us-hospitals